our Premium Content: News alerts, weekly reports and conference planners

GENE:

HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)

News alerts, weekly reports and conference planners

22h

Human papillomavirus 16 E6 oncoprotein promotes up-regulation of RNA-binding protein Sam68 in head and neck cancer. (PubMed, Front Microbiol)

In conclusion, our results suggest an interplay between the splicing machinery and HPV16 E6*I in HNSCC. These new observations are crucial for the development of novel therapeutic strategies based on SAM68 inhibitors.

22 hours ago

Journal

SRSF2 (Serine and arginine rich splicing factor 2) • KHDRBS1 (KH RNA Binding Domain Containing, Signal Transduction Associated 1) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • SRSF3 (Serine And Arginine Rich Splicing Factor 3)

18d

1,2,3,6-Tetragalloylglucose inhibits hnRNPA2B1/TRAIL Axis to attenuate apoptosis and barrier dysfunction in intestinal epithelial cells: A potential therapeutic avenue for IBD. (PubMed, Cell Signal)

The study results suggest that A2B1 plays a crucial role in IBD by modulating TRAIL mRNA, leading to IECs apoptosis and intestinal barrier dysfunction. Targeting the A2B1-TRAIL interaction with small-molecule inhibitors like TeGG offers a novel and promising therapeutic approach for the treatment of IBD.

18 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)

25d

A LNK-CBL-HNRPA2B1-GPX4 signaling axis mediates dopaminergic neuron vulnerability to ferroptosis in Parkinson's disease. (PubMed, Redox Biol)

In PD models, lifitegrast administration or genetic ablation of LNK was observed to mitigate dopaminergic neurodegeneration. These findings define the LNK-CBL-HNRNPA2B1-GPX4 axis in ferroptotic regulation and support LNK as a potential therapeutic target in PD.

25 days ago

Journal

GPX4 (Glutathione Peroxidase 4) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)

25d

Machine learning-based comprehensive analysis of m6A RNA methylation regulators in colorectal cancer: implications for prognosis, immune microenvironment, and immunotherapy response. (PubMed, Exp Biol Med (Maywood))

Our systematic machine learning analysis demonstrates that m6A regulators can effectively predict CRC prognosis and immunotherapy response. The eight-gene signature provides a practical tool for clinical risk assessment and treatment decision-making.

25 days ago

Journal • IO biomarker

CD8 (cluster of differentiation 8) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2) • VIRMA (Vir Like M6A Methyltransferase Associated)

Tumor Extracellular Vesicles lncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via m6A-Dependent hnRNPA2B1/COX-2 Axis. (PubMed, Adv Sci (Weinh))

Combination with EP2/EP4 antagonists produced enhanced anti-metastatic effects. These findings establish EVs-derived lncOSLMT as a key regulator of inflammatory PMN formation in the lung and highlight the potential of LF-RES-siRNA nanoparticles as a targeted anti-metastatic therapy in osteosarcoma.

1 month ago

Journal

PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)

Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in m6A-mediated OSCC treatment. (PubMed, Med Oncol)

STM2457 and APS enhance the inhibitory effects on OSCC progression by targeting the METTL3/HNRNPA2B1/FOXQ1 axis, offering a potential therapeutic strategy that integrates precision oncology with traditional herbal medicine. Further mechanistic and clinical studies are warranted to validate these findings.

1 month ago

Journal

CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • METTL3 (Methyltransferase Like 3)

DERL3 exacerbates glioblastoma malignancy through endoplasmic reticulum stress-dependent mechanisms. (PubMed, Am J Cancer Res)

Targeting this axis may offer novel therapeutic strategies to overcome treatment resistance, providing significant translational potential for improving glioma management. This study advances our understanding of stress response mechanisms in tumorigenesis and underscores the clinical relevance of ER stress-related pathways in precision oncology.

1 month ago

Journal

HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)

2ms

Expression and association of HNRNPA2B1 with clinical prognosis in breast cancer: An evaluation based on the TCGA and GEO databases. (PubMed, Medicine (Baltimore))

Additionally, a multivariate Cox regression model was used to establish a relationship with HNRNPA2B1 expression. This study underscores the critical role of HNRNPA2B1 in BC biology and its potential as a prognostic marker and therapeutic target, warranting further investigation into its mechanistic pathways and clinical applications.

2 months ago

Journal

HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)

2ms

UBE2I promotes immune infiltration and tumor progression in thyroid cancer and modulates hnRNPA2B1 SUMOylation. (PubMed, J Biol Chem)

In vivo, downregulation of UBE2I reduced tumor growth and the level of CD206. Taken together, our findings suggest that UBE2I promotes growth, migration, invasion, and M2 polarization of macrophages in THCA cells, potentially through a mechanism involving SUMOylation and the subsequent cytoplasmic localization of hnRNPA2B1.

2 months ago

Journal

MRC1 (Mannose Receptor C-Type 1) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • UBE2I (Ubiquitin Conjugating Enzyme E2 I)

3ms

METTL3-mediated m6A modification regulates OSCC progression via the HNRNPA2B1/FOXQ1 axis. (PubMed, Sci Rep)

METTL3-mediated m6A modification promotes OSCC progression by stabilizing HNRNPA2B1 and FOXQ1 mRNA, driving EMT and malignancy. The METTL3/HNRNPA2B1/FOXQ1 axis is a potential diagnostic and therapeutic target for OSCC, offering novel insights into epigenetic regulation and treatment strategies.

3 months ago

Journal

HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • METTL3 (Methyltransferase Like 3)

3ms

HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase. (PubMed, J Proteome Res)

In conclusion, this investigation provides a comprehensive overview of the protein phosphorylation cascades regulated by HNRNPA2B1 in MM, identifying CK2 as a crucial kinase target. Inhibiting CK2 kinase not only affects MM cell proliferation and apoptosis but also induces ER stress and autophagy, providing novel insights into MM pathogenesis.

3 months ago

Journal

HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)

3ms

Radiotherapy affects the ELAVL1-mediated autophagy pathway by promoting the release of LINC01943 exosomes in breast cancer cells to accelerate the M2 polarization of macrophages. (PubMed, Med Oncol)

In macrophages, overexpressed ELAVL1 promoted autophagy, and the autophagy activator Rapamycin reversed LINC01943-induced M2 polarization. Overall, this study found that RT upregulates hnRNPA2B1 to stabilize LINC01943 expression and enhance its Exo-mediated release, which subsequently inhibits ELAVL1-dependent autophagy in macrophages, accelerating M2 polarization.

3 months ago

Journal

CD163 (CD163 Molecule) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • TGFB1 (Transforming Growth Factor Beta 1) • CCL22 (C-C Motif Chemokine Ligand 22) • ELAVL1 (ELAV Like RNA Binding Protein 1) • MRC1 (Mannose Receptor C-Type 1) • BECN1 (Beclin 1) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)

sirolimus